XM46X2ICD-11 MMS 2026-01
Ubrogepant
Index terms
- Ubrogepant
Sibling codes
XM10Z6– ElotuzumabXM1D23– EptinezumabXM1GA2– PanitumumabXM1WL2– Gemtuzumab ozogamicinXM2065– AvelumabXM2FU8– TrastuzumabXM2KB4– OfatumumabXM3AY3– RituximabXM3DU2– OlaratumabXM3JP4– MogamulizumabXM3VL3– CetuximabXM47L7– FremanezumabXM4ES5– DaratumumabXM4W34– AtogepantXM4XM4– GalcanezumabXM52L2– EdrecolomabXM5JH7– IpilimumabXM5ST9– BevacizumabXM5VT7– Brentuximab vedotinXM5WX2– AlemtuzumabXM5WX4– NecitumumabXM6618– PertuzumabXM6ES5– ObinutuzumabXM6H29– Trastuzumab emtansineXM6M26– NivolumabXM6PT2– ErmekumabXM6Y05– RamucirumabXM74W8– DinutuximabXM7NY5– DurvalumabXM8648– Inotuzumab ozogamicinXM8C95– RimegepantXM8LF5– ErenumabXM8SU2– AtezolizumabXM8UG5– PembrolizumabXM9BU9– BlinatumomabXM9P40– CatumaxomabXM9Z80– Cemiplimab
Foundation entity
Part of: XM6WT8: Agents primarily affecting blood constituents or immune system › XM6S30: Medicaments › X: Extension Codes